

IQNovate Limited Begins Trading in U.S. Through Launch of ADRs

SYDNEY, Australia, December 18, 2012 -- IQNovate Limited (NSX: IQN, OTC: IQNDY), a life science organization providing contract drug development services and scientific advice to the global Biopharmaceutical industry, announced today that Mergent's Editorial Board has approved IQNovate for a listing in Mergent Manuals and News Reports™. IQNovate's corporate profile, which includes descriptive text data as well as news and financial statements, will be accessible via Mergent's online and print products.

As part of Mergent's listing services, the new description will be highlighted separately on www.mergent.com with an active hyperlink back to IQNovate's website.

The Mergent Industrial Manual and News Reports is a recognized securities manual in 39 U.S. states for purposes of Blue Sky Manual Exemption. First published in 1918, and formerly known as Moody's™ Manuals and News Reports, the publication was rebranded as Mergent Manuals and News Reports when Mergent, Inc. acquired Moody's Financial Information Services division in 1998. IQNovate's listing will aid the U.S. brokerage community in making a market for the company's ADRs. However, it is recommended that brokers confirm with their compliance or legal department concerning "Blue Sky" laws in specific states and other regulatory laws that might affect them.

For further information, please contact:

Con Tsigounis, Investor Relations. Telephone: +61 (2) 8239-5400

About IQNovate

IQNovate Limited is a life science organization, providing contract drug development services and scientific advice to the global Biopharmaceutical industry. The company also extends a premium advisory service to institutional capital investors on biotech investment strategy. IQNovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organizations. IQNovate focuses on every segment of the drug life cycle, from the preclinical stage to clinical, right through to RRC, bridging science with business and beyond.

About Mergent, Inc.

Mergent, Inc. is a leading provider of business and financial data on global publicly listed companies. Based in the United States, the company maintains a strong global presence, with offices in New York, Charlotte, San Diego, London, Tokyo and Melbourne. Founded in 1900, Mergent operates one of the longest continuously collected databases of descriptive and fundamental information on domestic and international companies, pricing and terms and conditions data on fixed income and equity securities, and corporate action data. In addition, Mergent's Indxis subsidiary develops and licenses equity and fixed income investment products based on its proprietary investment methodologies.

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQNovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQNovate Limited